Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative colitis trial
Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative colitis trial
Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative colitis trial
Submitted by
admin
on March 13, 2018 - 11:51am
Source:
Fierce Biotech
News Tags:
Protalix
anti-TNF
clinical trials
ulcerative colitis
OPRX-106
Headline:
Protalix’ oral anti-TNF drug hits the mark in phase 2 ulcerative colitis trial
Do Not Allow Advertisers to Use My Personal information
